Marker Therapeutics (MRKR) to Release Quarterly Earnings on Monday

Marker Therapeutics (NASDAQ:MRKR) is expected to be announcing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $1.0040 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 7:00 AM ET.

Marker Therapeutics (NASDAQ:MRKR) last announced its earnings results on Wednesday, March 18th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.17. The business had revenue of $1.10 million during the quarter, compared to analyst estimates of $0.68 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%. On average, analysts expect Marker Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Marker Therapeutics Price Performance

MRKR stock opened at $1.34 on Monday. The company has a market cap of $22.34 million, a P/E ratio of -1.58 and a beta of 1.42. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.07. The stock’s fifty day moving average price is $1.59 and its 200-day moving average price is $1.30.

Institutional Trading of Marker Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Marker Therapeutics in the third quarter worth about $25,000. Two Sigma Investments LP bought a new position in shares of Marker Therapeutics in the third quarter worth about $33,000. Jane Street Group LLC purchased a new position in shares of Marker Therapeutics during the 2nd quarter valued at about $33,000. XTX Topco Ltd grew its stake in shares of Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after acquiring an additional 36,269 shares during the period. Finally, LPL Financial LLC grew its stake in shares of Marker Therapeutics by 41.7% during the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after acquiring an additional 24,500 shares during the period. Institutional investors own 22.39% of the company’s stock.

Analyst Upgrades and Downgrades

MRKR has been the topic of a number of recent research reports. Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a research report on Monday, December 8th. Wall Street Zen upgraded shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, HC Wainwright initiated coverage on shares of Marker Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.25.

Marker Therapeutics News Roundup

Here are the key news stories impacting Marker Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $10.00 price target while publishing detailed quarterly and long‑term EPS model updates — a high-profile analyst backing that can attract buyers and liquidity. HC Wainwright research (via MarketBeat)
• Positive Sentiment: Brookline Cap M boosted its FY2026 EPS forecast for MRKR (revising the year loss from roughly ($2.74) to ($1.53)), signaling expectations for a smaller-than-previously-forecast cash burn or improved near‑term operating performance. Brookline Cap M note (via MarketBeat)
• Neutral Sentiment: HC Wainwright published quarterly EPS forecasts for 2027 (Q1: ($0.33), Q2: ($0.36), Q3: ($0.38), Q4: ($0.30)) and a FY2030 EPS view of ($0.75) — useful modeling inputs but they still project ongoing losses for several years. HC Wainwright forecasts (via MarketBeat)
• Neutral Sentiment: Aggregator coverage summarized analyst Q2 forecasts for MRKR; these consensus/estimates pieces are informational and help set expectations ahead of upcoming reports. Equities Analysts Issue Forecasts for MRKR Q2 Earnings
• Negative Sentiment: Consensus still forecasts a full‑year loss (approx. ($0.65) EPS), and quarter-by-quarter models remain negative — continued losses and negative margins could limit valuation multiple expansion and keep the stock volatile. Consensus estimates (via MarketBeat)
• Negative Sentiment: Historical metrics show large negative margins and negative ROE (company remains unprofitable), meaning any deterioration in operating results or funding concerns would weigh on the share price. Company fundamentals (via MarketBeat)

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.